Sutro Biopharma, Inc. (STRO) 株式分析

企業概要

Sutro Biopharma, Inc. operates primarily within the oncology sector, focusing on the development of site-specific and novel-format antibody drug conjugates (ADCs) that leverage proprietary integrated cell-free protein synthesis platforms known as XpressCF and XpressCF+. The company functions in the healthcare industry, specifically within the biotechnology sub-sector, where it advances therapeutic candidates designed to target cancer cells with higher precision while minimizing systemic toxicity. As a publicly traded entity with a market capitalization of $448.14M, Sutro Biopharma, Inc. maintains an operational scale involving 137 employees and reported total annual revenue of $102.48M over the trailing twelve months. The relatively modest market cap combined with the specific revenue figure suggests the company is in a growth-phase biotechnology environment, where capital allocation is heavily weighted toward research and development rather than immediate profit generation, which is typical for firms pioneering novel conjugation technologies in a competitive therapeutic landscape.

財務健全性

The company reported revenue of $102.48M for the trailing twelve months, yet this top-line performance masks significant underlying losses, as evidenced by a net income of -$191,086,000 and an EBITDA of -$97,628,000. The substantial gap between the $102.48M in revenue and the -$191.09M in net income reveals a highly aggressive cost structure, likely driven by high expenses in clinical trials, manufacturing scale-up, and platform development that far exceed current revenue generation capabilities. Free cash flow stands at -$112,393,376, indicating that the company is burning cash at a rapid pace, which limits immediate financial flexibility and necessitates ongoing access to capital markets or existing cash reserves to fund operations. The company's margins reflect this financial pressure, with a gross margin of -62.4%, an operating margin of -289.0%, and a profit margin of -186.5%, all of which indicate that the cost of goods sold and operating expenses are significantly outpacing sales, a common characteristic in early-stage biotech but one that poses a liquidity risk. Despite these losses, the balance sheet shows a cash position of $141.43M against total debt of $15.67M, suggesting the firm is currently less leveraged than its losses imply, though the negative debt-to-equity ratio indicates the company has no tangible book value. The current ratio of 2.01 suggests a conservative approach to short-term liquidity management, as the company holds more than twice the value of current liabilities in current assets. Furthermore, the return on equity is marked as N/A due to negative equity, while the return on assets is -23.4%, revealing that management is currently utilizing assets to generate losses rather than returns, a metric that typically deteriorates during the pre-commercialization phase of drug development.

バリュエーション評価

Valuation metrics for Sutro Biopharma, Inc. present a complex picture, with a trailing P/E ratio of N/A and a forward P/E of -10.91, implying that earnings are currently negative and that future earnings projections are also insufficient to generate a positive multiple based on current share prices. The price-to-book ratio stands at -1.75, which indicates that the market is pricing the company significantly below its net asset value, a scenario often seen in loss-making firms where book value does not reflect the potential value of pipeline assets. Alternative valuation metrics such as the price-to-sales ratio of 4.37 and an EV/EBITDA of -3.30 suggest that investors are willing to pay a premium relative to sales, potentially betting on the success of the lead product candidate despite the lack of profitability. The stock's trading range over the past year is defined by a 52-week high of $27.81 and a 52-week low of $5.20, meaning the current share price sits at a level that reflects extreme volatility and uncertainty regarding the company's near-term commercialization milestones. The beta value of 1.31 indicates that the stock is 31% more volatile than the broader market, suggesting that price movements will likely be amplified by market swings, which is consistent with the high-risk profile of a small-cap biotechnology firm with no current product sales.

Growth & Income

Regarding growth metrics, the company experienced a revenue growth rate of -21.4% year-over-year, while earnings growth is recorded as N/A due to the transition from profitability to significant losses. The fact that earnings growth is not applicable while revenue has contracted implies that the cost structure has deteriorated faster than sales, leading to a compression in profitability rather than a traditional growth trajectory. Sutro Biopharma, Inc. does not pay dividends, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, which means the company reinvests all available resources and any remaining cash flow back into research and development and platform expansion rather than returning capital to shareholders. This non-dividend profile aligns with the biotechnology sector's standard practice of prioritizing long-term asset accumulation and clinical progress over immediate income distribution to investors. Overall, the growth and income profile of Sutro Biopharma, Inc. is characterized by declining revenue, negative cash flow, and a complete absence of dividend income, reflecting a capital-intensive strategy focused entirely on advancing its oncology pipeline without current commercial returns.